Long-term data from PACIFIC phase III trial at ASCO showed 33% of NSCLC patients remained progression-free at five years – AstraZeneca
Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351
Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot accept responsibility for the authenticity of the content matter.
Copyright: The copyright of the material on this site rests with the author unless otherwise indicated. It is a breach of copyright to use any material from this site without prior written consent.